FGF Family: From Drug Development to Clinical Application

Qi, Hui; Jin, Zi; Li, Xiaokun; Liu, Changxiao; Wang, Xiaojie

doi:10.3390/ijms19071875

Cited by 135 publications

(111 citation statements)

References 98 publications

(115 reference statements)

Supporting

Mentioning

106

Contrasting

Unclassified

Order By: Relevance

“…All FGFs, except FGF11, FGF12, FGF13, and FGF14 act through their specific receptors (FGFRs), including mitogenesis and non-mitogenic effects (Yun et al, 2010). The FGF ligands elicit their activity by using four transmembrane tyrosine kinase receptors FGFR1, FGFR2, FGFR3, and FGFR4 (Hui et al, 2018). The activated FGFRs will transduce the signals through three dominant pathways including RAS/MAPK, PI3k/AKT, and PLCγ (Yun et al, 2010;Li et al, 2016).…”

Section: Fgf Signaling Pathway In Pscsmentioning

confidence: 99%

FGF Signaling Pathway: A Key Regulator of Stem Cell Pluripotency

Mossahebi-Mohammadi

Quan

Zhang

et al. 2020

Front. Cell Dev. Biol.

Self Cite

201

153

View full text Add to dashboard Cite

Section: Fgf Signaling Pathway In Pscsmentioning

confidence: 99%

FGF Signaling Pathway: A Key Regulator of Stem Cell Pluripotency

Mossahebi-Mohammadi

Quan

Zhang

et al. 2020

Front. Cell Dev. Biol.

Self Cite

201

153

View full text Add to dashboard Cite

“…The protein encoded by this gene is a member of the fibroblast growth factor (FGF) family. FGF family members bind heparin and possess broad mitogenic and angiogenic activities [22] . FGF2 has also been implicated in diverse biological processes, such as limb and nervous system development, wound healing, and tumor growth [23] .…”

Section: Discussionmentioning

confidence: 99%

MiR-203 inhibits the proliferation, invasion, and migration of pancreatic cancer cells by down-regulating fibroblast growth factor 2

Zhao

Chen

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Aberrant fibroblast growth factor 2 (FGF2) expression is a major cause of poor prognosis in pancreatic cancer. MiR-203 is a newly discovered microRNA (miRNA) that can affect the biological behavior of tumors. This study investigated whether miR-203 can regulate FGF2 expression and its role in pancreatic cancer cell proliferation, apoptosis, invasion, and migration.Methods: MiR-203 expression in different cell lines was examined by qRT-PCR, followed by the establishment of knockdown and overexpression cell models. We used the CCK-8 assay to examine cell proliferation and the annexin V-APC/7-AAD doublestaining method to detect apoptosis. In addition, we used wound healing and transwell assays to investigate the effects of miR-203 on the migration and invasion of pancreatic cancer cells. The effects of miR-203 knockdown and overexpression on FGF2 mRNA expression were detected by qRT-PCR. We also overexpressed FGF2 and examined the effects of FGF2 overexpression on the proliferation, apoptosis, invasion, and migration of pancreatic cancer cells. The binding of miR-203 to FGF2 was assessed by a luciferase reporter assay. Results:We found that the miR-203 expression level was significantly down-regulated in pancreatic cancer cells compared to normal pancreatic cells. Functionally, the knockdown of miR-203 inhibited cell proliferation and increased apoptosis. Equally important, miR-203 reduced the migration and invasion of pancreatic cancer cells. In addition, we found that miR-203 overexpression inhibited FGF2 expression in pancreatic cancer cells by qRT-PCR. FGF2 overexpression significantly affected the proliferation, invasion, and metastasis of pancreatic cancer cells. Mechanistically, miR-203 base-paired with the FGF2 mRNA, resulting in the knockdown of the FGF2 mRNA and the down-regulation of the FGF2 protein. Conclusions:MiR-203 inhibits FGF2 expression, regulates the proliferation of pancreatic cancer cells, and inhibits the invasion and metastasis of pancreatic cancer cells.

show abstract

“…The preliminary mechanisms through which aFGF promotes the wound healing include aFGF-stimulated secretion of TGF-b and PCNA proteins from the damaged skin and the promotion of capillary and fibroblast proliferation (Xie et al, 2011). Our group previously developed a lyophilized rh-aFGF, which was approved by the Chinese Food and Drug Administration in 2006 for the treatment of deep, partial-thickness burns and skin graft donor sites (Ma et al, 2007;Hui et al, 2018a). This marketed rh-aFGF is a topical lyophilization agent, applied in the form of a spray.…”

Section: Introductionmentioning

confidence: 99%

Long-Term Toxicity Study of Topical Administration of a Highly-Stable rh-aFGF Carbomer 940 Hydrogel in a Rabbit Skin Wound Model

Zhang

Huang

et al. 2020

Front. Pharmacol.

Self Cite

View full text Add to dashboard Cite

We developed a highly stable recombinant human acidic fibroblast growth factor (rh-aFGF) carbomer 940 hydrogel for wound healing. This study aimed to reveal toxicity target organs and the toxicity dose-response in the long-term administration of rh-aFGF carbomer 940 hydrogel in a rabbit skin wound model. New Zealand rabbits were topically administrated rh-aFGF carbomer 940 hydrogel at a daily dose of 900 IU/cm 2 , 1,800 IU/cm 2 , and 3,600 IU/cm 2 for 28 days. Lyophilized rh-aFGF agent was used as the positive control group. General behavior, serum chemistry, skin irritation, immunogenicity, immunotoxicity, and histopathology were analyzed at designated time points. Results revealed that food intake, body weight, body temperature, heart rate, and eye examinations were all normal, suggesting no obvious toxicity induced by the rh-aFGF hydrogel. Medium and high dose rh-aFGF hydrogel groups and the positive control group displayed increased cell numbers in the local lymph nodes near the site of administration, likely caused mesenteric lymph node follicular hyperplasia, and this observation was alleviated after 14 days of recovery. Immunogenicity studies demonstrated that the serum antibody titer against rh-aFGF increased with the duration and number of drug applications but were not neutralization antibodies. After administration stopped, antibody titer decreased and disappeared in some mice. In summary, the safe dose for long-term administration of rh-aFGF carbomer 940 hydrogel for persistently damaged skin was 900 IU/cm 2 , which is 10 times that of the proposed clinical dosing.

show abstract

FGF Family: From Drug Development to Clinical Application

Cited by 135 publications

References 98 publications

FGF Signaling Pathway: A Key Regulator of Stem Cell Pluripotency

FGF Signaling Pathway: A Key Regulator of Stem Cell Pluripotency

MiR-203 inhibits the proliferation, invasion, and migration of pancreatic cancer cells by down-regulating fibroblast growth factor 2

Long-Term Toxicity Study of Topical Administration of a Highly-Stable rh-aFGF Carbomer 940 Hydrogel in a Rabbit Skin Wound Model

Contact Info

Product

Resources

About